Had previously seen Q4 cont-op revenue of $77.5M-$80.5M. Consensus for Q4 revenue is $78.5M. CEO Brian W. Adams said, "We finished 2022 on a strong note, with our preliminary unaudited Q4 estimated revenue exceeding the high-end of the guidance range we provided on November 3, 2022. Entering 2023, we are encouraged by the underlying growth of our core PACE market and the exciting opportunities in adjacent markets to provide solutions to help manage the most complex patients in our healthcare system."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TRHC:
